Actavis Deal Brings Generics “DNA” To Primary Care Opportunity, CEOs Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Amid challenges in the generics sector, the proposed merger of Forest and Actavis creates uncertainty about how the companies will market their primary care drugs.